CRBU, US1420381089

Caribou Biosciences stock draws a Moderate Buy consensus from analysts

Published on 10/04/2026 at 19:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bank of America reported 1.41 million CRBU shares in a Q2 filing dated October 1, 2026. Five analysts set a USD 7.75 average target against a USD 1.22 close.

CRBU, US1420381089, Illustration mit AI erstellt.

Caribou Biosciences stock (ISIN US1420381089) closed at USD 1.22 on Nasdaq on October 2, 2026, leaving the company with a USD 121.0 million market capitalization. The latest institutional filing adds a fresh ownership signal: MarketBeat reported on October 1, 2026, that Bank of America purchased 1,410,958 Caribou shares during the second quarter.

Institutional ownership reaches 77.51 percent

The Bank of America position represented 1.42 percent of Caribou at the end of the second quarter and carried a reported value of USD 2.483 million, according to MarketBeat. The same filing coverage put total institutional ownership at 77.51 percent, while BlackRock acquired a reported 7.82 million shares during the second quarter.

The ownership data matter because Caribou remains a clinical-stage biotechnology company rather than a commercial drug business. Its platform uses CRISPR genome editing and its pipeline centers on off-the-shelf CAR-T therapies for hematologic malignancies, a focus described by Caribou Biosciences on its investor-relations page.

Q2 loss beats EPS estimate

Caribou's second-quarter 2026 results showed diluted EPS of negative USD 0.24, compared with a consensus estimate of negative USD 0.32, an improvement of USD 0.08 per share. Revenue was USD 1.50 million versus an expected USD 2.28 million, according to MarketBeat. The mixed result places greater weight on clinical progress and financing capacity than on current sales.

For the quarter ended June 30, 2026, standardized financial data show total revenue of USD 1.499 million, net income of negative USD 24.282 million and cash of USD 26.194 million. Operating cash flow was negative USD 22.787 million in the same period, keeping the cash balance central to the company story.

Moderate Buy meets a wide target gap

MarketBeat reported on September 19, 2026, that five analysts held a Moderate Buy consensus, with three Buy ratings, one Strong Buy and one Sell. The average 12-month target was USD 7.75, while the stock price was USD 1.22 on October 2, 2026, making the target USD 6.53 above the Nasdaq close.

CRBU stays near its yearly low

CRBU finished the October 2 session at USD 1.22 after opening at USD 1.24, with a session range of USD 1.22 to USD 1.24. The 52-week range was USD 1.22 to USD 3.54, while trading volume reached 866,390 shares and the reference price was unchanged from the prior close.